Delonix Bioworks and Olymvax Biopharmaceuticals Announce Strategic Collaboration on Next-Generation Genetically Engineered Pertussis Vaccines

Delonix Bioworks, a synthetic biology–driven biotechnology company focused on innovative bacterial vaccines, announced a strategic collaboration and licensing agreement with Olymvax Biopharmaceuticals to advance next-generation genetically engineered pertussis vaccines.

The partnership combines Delonix’s proprietary bacterial vaccine discovery platforms with Olymvax’s established manufacturing and commercialization capabilities, aiming to accelerate the development of novel pertussis vaccine candidates and future multivalent combination products.

Delonix has built strong technical capabilities in genetically engineered pertussis vaccine development through years of focused research. Leveraging its pathogen genome editing technologies, the company has generated vaccine candidates demonstrating robust immunogenicity and protective efficacy in preclinical studies, supported by multiple granted patents.

Through this collaboration, Olymvax plans to accelerate program development, with the goal of advancing engineered DTaP combination vaccine candidates toward clinical evaluation, expanding future immunization options for both pediatric and adult populations.

“We are pleased to partner with Olymvax Biopharmaceuticals,” said Qiubin Lin, Ph.D., Founder and CEO of Delonix Bioworks. “Olymvax’s strong industrialization capabilities provide a solid foundation for translating our genetically engineered pertussis vaccine programs into clinical development. This collaboration reflects our shared commitment to advancing innovative bacterial vaccines.”

Fan Fan, Vice Chairwoman of Olymvax Biopharmaceuticals, commented, “Delonix has demonstrated strong innovation in synthetic biology–enabled bacterial vaccine development. By combining Delonix’s R&D strengths with Olymvax’s manufacturing expertise, we aim to accelerate the transition of next-generation pertussis vaccines from laboratory to clinic.”

About Delonix Bioworks

^{Delonix Bioworks is a clinical-stage biotechnology company developing next-generation genetically engineered bacterial vaccines. Leveraging its proprietary OMV Plus® platform and pathogen genome editing technologies, the company advances a diversified pipeline addressing critical unmet needs, including vaccines for meningococcal B, pertussis, gonorrhea, and Klebsiella pneumoniae.}

For more information, please visit https://delonixbio.com/

About Olymvax Biopharmaceuticals

Olymvax Biopharmaceuticals is a leading human vaccine company in China with integrated capabilities across vaccine R&D, manufacturing, and commercialization.